CC · available-data snapshot
The Chemours Company (CC): Available-Data Snapshot
TickerWorth does not publish a DCF fair value for The Chemours Company (CC); the reason is set out below. What its filings and market data do show is below. The snapshot also sets out its trading multiples against 5 peers. Snapshot as of Oct 19, 2026.
Model by Miraaj Patel · generated from public market data · Updated Oct 19, 2026 · How these pages are made
Why is there no fair value for CC?
We do not publish a fair value for The Chemours Company. What we can say from its filings and market data is below.
What is CC's TickerWorth Score?
A weaker business than most companies
Compared with Basic Materials companies in US
Its strongest point: trades below our estimate of what it's worth. Its weakest: profitability is weak.
- Value · 79 of 100
Cheaper than 79% of Basic Materials companies in US
- Price vs worth · 100 of 100
- Quality · 9 of 100
More profitable than 9% of Basic Materials companies in US
- Financial health · 24 of 100
Financially stronger than 24% of Basic Materials companies in US
- Growth · 6 of 100
Growing faster than 6% of Basic Materials companies in US
- Momentum · 15 of 100
Outperformed 15% of Basic Materials companies in US over the past year
Confidence: Medium confidence · Scored
Get the Undervalued Company of the Week.
- Price
- $12.78
- Market cap
- $1,
922, 624, 512 - 52-week high
- $28.67
- 52-week low
- $10.44
- Currency
- USD
- Exchange
- NYSE
Snapshot of Oct 19, 2026, quote time not published · Prices are delayed.
What we can say
We don't publish a discounted-cash-flow fair value for The Chemours Company (CC) because the free data sources we rely on don't expose the multi-year financials a DCF needs — common for small or thinly-covered listings. Rather than invent numbers, this page shows an honest snapshot of what the public data does support: the current price and size, any relative valuation multiples that exist, a book-value view, and a price-based read. Treat it as a descriptive starting point, not a valuation and not investment advice.
Read the full reasoning
On the numbers we do have, CC trades at a recent price of $12.78, a market capitalisation of about $1,922,624,512, sitting 13% of the way up its 52-week range ($10.44–$28.67), on the NYSE.
The standard alternative to a DCF is relative valuation — comparing CC's trading multiples against a sector benchmark. Here that gives Fwd P/E of 6.8× (cheaper than the peer median of 20.8×); P/S of 0.3× (cheaper than the peer median of 4.8×); EV/EBITDA of 11.1× (cheaper than the peer median of 18.4×); Dividend yield of 2.7% (cheaper than the peer median of 1.0%). A cheaper multiple than peers can flag a discount or a market that expects weaker growth; it is a comparison, not a recommendation.
Finally, a price-based read — explicitly not a valuation. CC is in a down-trend (price below both its 50- and 200-day averages), trading -55.4% from its 52-week high. Over the past year the stock is -4.3%. Moving-average trend and 52-week position describe where the stock has traded; they say nothing about what it is worth.
CC vs peers
Sector benchmark (bellwethers, not direct competitors).
| Multiple | CC | Peer median | Read |
|---|---|---|---|
| Fwd P/E | 6.8× | 20.8× | cheaper than |
| P/S | 0.3× | 4.8× | cheaper than |
| EV/EBITDA | 11.1× | 18.4× | cheaper than |
| Dividend yield | 2.7% | 1.0% | cheaper than |
What does The Chemours Company do?
What does it do?
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. The company operates through three segments: Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials. It operates in the Specialty Chemicals industry (Basic Materials sector), headquartered in United States. The company employs roughly 5,700 people.
How does it make money?
The business turns $5.8B in annual revenue into profit. Out of every $100 of sales, about $1 is left as operating profit (operating margin of 1.1%), after a 15% gross margin on the products/services it sells. After all costs, taxes and interest, -5.2% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks mixed: comfortably covers its short-term bills (1.7× current ratio), and is currently lossmaking.
Who at CC filed insider trades?
| Date | Insider | Relationship | What happened | Value | Filing |
|---|---|---|---|---|---|
| Will David | Chief Accounting Officer | Shares withheld (tax) | $36,972.24 | Form 4 for Will David (opens sec.gov in a new tab) | |
| Familiar Calderon Gerardo | See Remarks | Open-market buy | $30,050.55 | Form 4 for Familiar Calderon Gerardo (opens sec.gov in a new tab) | |
| Dignam Denise | Director, Chief Executive Officer | Open-market buy | $50,501.10 | Form 4 for Dignam Denise (opens sec.gov in a new tab) | |
| Cowan Alister | Director | Open-market buy | $203,060.00 | Form 4 for Cowan Alister (opens sec.gov in a new tab) | |
| Foley Michael Robert | See Remarks | Open-market buy | $29,999.93 | Form 4 for Foley Michael Robert (opens sec.gov in a new tab) | |
| Martinko Joseph T. | See Remarks | Open-market buy | $30,008.73 | Form 4 for Martinko Joseph T. (opens sec.gov in a new tab) |
A disclosure, not a signal to trade. Source: SEC EDGAR (Form 4). Older filings and the 90-day buying-and-selling read are part of Pro. See plans
Companies we do put a number on
Not investment advice. TickerWorth Score is a model output.
A descriptive, available-data snapshot and relative comparison — NOT a DCF, NOT a price target, and NOT investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public market data that can be wrong, stale or incomplete.